DCLK1 and neoplasm: Through IL13 and PDG2 secretion, and the DCLK1/Hippo interaction, TCs may influence the expression of these checkpoint molecules in the tumor microenvironment, and targeting them could help overcome TC-mediated immunomodulation [173,178].